Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma.

Kadota K, Sima CS, Arcila ME, Hedvat C, Kris MG, Jones DR, Adusumilli PS, Travis WD.

Am J Surg Pathol. 2016 Dec;40(12):1579-1590.

2.

Resistance to imatinib in patients with chronic myelogenous leukemia and the splice variant BCR-ABL1(35INS).

Berman E, Jhanwar S, Hedvat C, Arcila ME, Wahab OA, Levine R, Maloy M, Ma W, Albitar M.

Leuk Res. 2016 Oct;49:108-12. doi: 10.1016/j.leukres.2016.08.006. Epub 2016 Aug 12.

3.

Detection of mutations in myeloid malignancies through paired-sample analysis of microdroplet-PCR deep sequencing data.

Cheng DT, Cheng J, Mitchell TN, Syed A, Zehir A, Mensah NYT, Oultache A, Nafa K, Levine RL, Arcila ME, Berger MF, Hedvat CV.

J Mol Diagn. 2014 Sep;16(5):504-518. doi: 10.1016/j.jmoldx.2014.05.006. Epub 2014 Jul 10.

4.

Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial.

Carvajal RD, Sosman JA, Quevedo JF, Milhem MM, Joshua AM, Kudchadkar RR, Linette GP, Gajewski TF, Lutzky J, Lawson DH, Lao CD, Flynn PJ, Albertini MR, Sato T, Lewis K, Doyle A, Ancell K, Panageas KS, Bluth M, Hedvat C, Erinjeri J, Ambrosini G, Marr B, Abramson DH, Dickson MA, Wolchok JD, Chapman PB, Schwartz GK.

JAMA. 2014 Jun 18;311(23):2397-405. doi: 10.1001/jama.2014.6096.

5.

Acute myeloid leukemia arising from a donor derived premalignant hematopoietic clone: A possible mechanism for the origin of leukemia in donor cells.

Dickson MA, Papadopoulos EB, Hedvat CV, Jhanwar SC, Brentjens RJ.

Leuk Res Rep. 2014 May 20;3(2):38-41. doi: 10.1016/j.lrr.2014.04.001. eCollection 2014.

6.

Association of quantitative assessment of the intrafollicular proliferation index with outcome in follicular lymphoma.

Kedmi M, Hedvat CV, Maragulia J, Zhang Z, Zelenetz AD.

Br J Haematol. 2014 Mar;164(5):646-52. doi: 10.1111/bjh.12667. Epub 2013 Dec 5.

PMID:
24303881
7.

Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing.

Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, Schnall-Levin M, White J, Sanford EM, An P, Sun J, Juhn F, Brennan K, Iwanik K, Maillet A, Buell J, White E, Zhao M, Balasubramanian S, Terzic S, Richards T, Banning V, Garcia L, Mahoney K, Zwirko Z, Donahue A, Beltran H, Mosquera JM, Rubin MA, Dogan S, Hedvat CV, Berger MF, Pusztai L, Lechner M, Boshoff C, Jarosz M, Vietz C, Parker A, Miller VA, Ross JS, Curran J, Cronin MT, Stephens PJ, Lipson D, Yelensky R.

Nat Biotechnol. 2013 Nov;31(11):1023-31. doi: 10.1038/nbt.2696. Epub 2013 Oct 20.

8.

Laboratory practice guidelines for detecting and reporting JAK2 and MPL mutations in myeloproliferative neoplasms: a report of the Association for Molecular Pathology.

Gong JZ, Cook JR, Greiner TC, Hedvat C, Hill CE, Lim MS, Longtine JA, Sabath D, Wang YL; Association for Molecular Pathology.

J Mol Diagn. 2013 Nov;15(6):733-44. doi: 10.1016/j.jmoldx.2013.07.002. Epub 2013 Aug 24.

9.

CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia.

Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, Bartido S, Stefanski J, Taylor C, Olszewska M, Borquez-Ojeda O, Qu J, Wasielewska T, He Q, Bernal Y, Rijo IV, Hedvat C, Kobos R, Curran K, Steinherz P, Jurcic J, Rosenblat T, Maslak P, Frattini M, Sadelain M.

Sci Transl Med. 2013 Mar 20;5(177):177ra38. doi: 10.1126/scitranslmed.3005930.

10.

Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions.

Busam KJ, Hedvat C, Pulitzer M, von Deimling A, Jungbluth AA.

Am J Surg Pathol. 2013 Mar;37(3):413-20. doi: 10.1097/PAS.0b013e318271249e.

PMID:
23211290
11.

Akt phosphorylates the transcriptional repressor bmi1 to block its effects on the tumor-suppressing ink4a-arf locus.

Liu Y, Liu F, Yu H, Zhao X, Sashida G, Deblasio A, Harr M, She QB, Chen Z, Lin HK, Di Giandomenico S, Elf SE, Yang Y, Miyata Y, Huang G, Menendez S, Mellinghoff IK, Rosen N, Pandolfi PP, Hedvat CV, Nimer SD.

Sci Signal. 2012 Oct 23;5(247):ra77. doi: 10.1126/scisignal.2003199.

12.

Objective quantification of the Ki67 proliferative index in neuroendocrine tumors of the gastroenteropancreatic system: a comparison of digital image analysis with manual methods.

Tang LH, Gonen M, Hedvat C, Modlin IM, Klimstra DS.

Am J Surg Pathol. 2012 Dec;36(12):1761-70. doi: 10.1097/PAS.0b013e318263207c.

PMID:
23026928
13.

Regulatory T cell infiltration predicts outcome following resection of colorectal cancer liver metastases.

Katz SC, Bamboat ZM, Maker AV, Shia J, Pillarisetty VG, Yopp AC, Hedvat CV, Gonen M, Jarnagin WR, Fong Y, D'Angelica MI, DeMatteo RP.

Ann Surg Oncol. 2013 Mar;20(3):946-55. doi: 10.1245/s10434-012-2668-9. Epub 2012 Sep 26.

14.

A case of synchronous pancreatic ductal adenocarcinoma and ovarian mucinous cystic neoplasm: use of kras mutation molecular phenotyping to demonstrate independent primary origin.

Lowery M, Klimstra D, Hedvat C, Jarnagin W, Chi D, O'Reilly EM.

Gastrointest Cancer Res. 2012 Mar;5(2):67-70. No abstract available.

15.

Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome.

Zhang SJ, Rampal R, Manshouri T, Patel J, Mensah N, Kayserian A, Hricik T, Heguy A, Hedvat C, Gönen M, Kantarjian H, Levine RL, Abdel-Wahab O, Verstovsek S.

Blood. 2012 May 10;119(19):4480-5. doi: 10.1182/blood-2011-11-390252. Epub 2012 Mar 19.

16.

Disruption of Abi1/Hssh3bp1 expression induces prostatic intraepithelial neoplasia in the conditional Abi1/Hssh3bp1 KO mice.

Xiong X, Chorzalska A, Dubielecka PM, White JR, Vedvyas Y, Hedvat CV, Haimovitz-Friedman A, Koutcher JA, Reimand J, Bader GD, Sawicki JA, Kotula L.

Oncogenesis. 2012 Sep 3;1:e26. doi: 10.1038/oncsis.2012.28.

17.

Importance of day 21 BM chimerism in sustained neutrophil engraftment following double-unit cord blood transplantation.

Avery S, Voss MH, Gonzales AM, Lubin M, Castro-Malaspina H, Giralt S, Kernan NA, Scaradavou A, Hedvat CV, Stevens CE, Barker JN.

Bone Marrow Transplant. 2012 Aug;47(8):1056-60. doi: 10.1038/bmt.2011.236. Epub 2011 Dec 5.

18.

Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation.

Doubrovina E, Oflaz-Sozmen B, Prockop SE, Kernan NA, Abramson S, Teruya-Feldstein J, Hedvat C, Chou JF, Heller G, Barker JN, Boulad F, Castro-Malaspina H, George D, Jakubowski A, Koehne G, Papadopoulos EB, Scaradavou A, Small TN, Khalaf R, Young JW, O'Reilly RJ.

Blood. 2012 Mar 15;119(11):2644-56. doi: 10.1182/blood-2011-08-371971. Epub 2011 Dec 2.

19.

Donor-derived lymphomatoid papulosis in a stem-cell transplantation recipient.

Camp BJ, Busam KJ, Brownell I, Koehne G, Hedvat C, Pulitzer MP.

J Clin Oncol. 2011 Dec 10;29(35):e855-8. doi: 10.1200/JCO.2011.37.7101. Epub 2011 Oct 31. No abstract available.

20.

Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization.

Tafe LJ, Janjigian YY, Zaidinski M, Hedvat CV, Hameed MR, Tang LH, Hicks JB, Shah MA, Barbashina V.

Arch Pathol Lab Med. 2011 Nov;135(11):1460-5. doi: 10.5858/arpa.2010-0541-OA.

PMID:
22032573
21.

Testis-isolated mantle cell lymphoma: a unique case.

Epstein AS, Hedvat C, Habib F, Hamlin P.

Clin Lymphoma Myeloma Leuk. 2011 Oct;11(5):439-41. doi: 10.1016/j.clml.2011.06.013. Epub 2011 Sep 8. No abstract available.

PMID:
21862436
22.

High frequency of IDH-1 mutation links glioneuronal tumors with neuropil-like islands to diffuse astrocytomas.

Huse JT, Nafa K, Shukla N, Kastenhuber ER, Lavi E, Hedvat CV, Ladanyi M, Rosenblum MK.

Acta Neuropathol. 2011 Sep;122(3):367-9. doi: 10.1007/s00401-011-0855-6. Epub 2011 Jul 14. No abstract available.

23.

Ddx18 is essential for cell-cycle progression in zebrafish hematopoietic cells and is mutated in human AML.

Payne EM, Bolli N, Rhodes J, Abdel-Wahab OI, Levine R, Hedvat CV, Stone R, Khanna-Gupta A, Sun H, Kanki JP, Gazda HT, Beggs AH, Cotter FE, Look AT.

Blood. 2011 Jul 28;118(4):903-15. doi: 10.1182/blood-2010-11-318022. Epub 2011 Jun 7.

24.

Late relapse in primary central nervous system lymphoma: clonal persistence.

Nayak L, Hedvat C, Rosenblum MK, Abrey LE, DeAngelis LM.

Neuro Oncol. 2011 May;13(5):525-9. doi: 10.1093/neuonc/nor014. Epub 2011 Mar 3.

25.

Blood consult: acute myeloid leukemia and the t(8;21)(q22;22).

Park JH, Hedvat CV, Tallman MS.

Blood. 2011 Mar 10;117(10):2775-7. doi: 10.1182/blood-2011-01-326819. Epub 2011 Feb 1. No abstract available.

26.

Digital microscopy: past, present, and future.

Hedvat CV.

Arch Pathol Lab Med. 2010 Nov;134(11):1666-70. doi: 10.1043/2009-0579-RAR1.1. Review.

PMID:
21043820
27.

PHF6 mutations in adult acute myeloid leukemia.

Van Vlierberghe P, Patel J, Abdel-Wahab O, Lobry C, Hedvat CV, Balbin M, Nicolas C, Payer AR, Fernandez HF, Tallman MS, Paietta E, Melnick A, Vandenberghe P, Speleman F, Aifantis I, Cools J, Levine R, Ferrando A.

Leukemia. 2011 Jan;25(1):130-4. doi: 10.1038/leu.2010.247. Epub 2010 Oct 29.

28.

HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans.

Marubayashi S, Koppikar P, Taldone T, Abdel-Wahab O, West N, Bhagwat N, Caldas-Lopes E, Ross KN, Gönen M, Gozman A, Ahn JH, Rodina A, Ouerfelli O, Yang G, Hedvat C, Bradner JE, Chiosis G, Levine RL.

J Clin Invest. 2010 Oct;120(10):3578-93. doi: 10.1172/JCI42442. Epub 2010 Sep 13.

29.

The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.

Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Coller HA, Cross JR, Fantin VR, Hedvat CV, Perl AE, Rabinowitz JD, Carroll M, Su SM, Sharp KA, Levine RL, Thompson CB.

Cancer Cell. 2010 Mar 16;17(3):225-34. doi: 10.1016/j.ccr.2010.01.020. Epub 2010 Feb 18.

30.

Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis.

Koppikar P, Abdel-Wahab O, Hedvat C, Marubayashi S, Patel J, Goel A, Kucine N, Gardner JR, Combs AP, Vaddi K, Haley PJ, Burn TC, Rupar M, Bromberg JF, Heaney ML, de Stanchina E, Fridman JS, Levine RL.

Blood. 2010 Apr 8;115(14):2919-27. doi: 10.1182/blood-2009-04-218842. Epub 2010 Feb 12.

31.

Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias.

Abdel-Wahab O, Manshouri T, Patel J, Harris K, Yao J, Hedvat C, Heguy A, Bueso-Ramos C, Kantarjian H, Levine RL, Verstovsek S.

Cancer Res. 2010 Jan 15;70(2):447-52. doi: 10.1158/0008-5472.CAN-09-3783. Epub 2010 Jan 12.

32.

Prognostic impact of proliferative index determined by quantitative image analysis and the International Prognostic Index in patients with mantle cell lymphoma.

Schaffel R, Hedvat CV, Teruya-Feldstein J, Persky D, Maragulia J, Lin D, Portlock CS, Moskowitz CH, Zelenetz AD.

Ann Oncol. 2010 Jan;21(1):133-9. doi: 10.1093/annonc/mdp495.

33.

A role for BRCA1 in uterine leiomyosarcoma.

Xing D, Scangas G, Nitta M, He L, Xu X, Ioffe YJ, Aspuria PJ, Hedvat CY, Anderson ML, Oliva E, Karlan BY, Mohapatra G, Orsulic S.

Cancer Res. 2009 Nov 1;69(21):8231-5. doi: 10.1158/0008-5472.CAN-09-2543. Epub 2009 Oct 20.

34.

PIK3CA mutation associates with improved outcome in breast cancer.

Kalinsky K, Jacks LM, Heguy A, Patil S, Drobnjak M, Bhanot UK, Hedvat CV, Traina TA, Solit D, Gerald W, Moynahan ME.

Clin Cancer Res. 2009 Aug 15;15(16):5049-59. doi: 10.1158/1078-0432.CCR-09-0632. Epub 2009 Aug 11.

35.

Synchronous follicular lymphoma, kaposi sarcoma, and castleman's disease in a HIV-negative patient with EBV and HHV-8 coinfection.

Koreishi AF, Saenz AJ, Arcila ME, Hedvat C, Fleming S, Teruya-Feldstein J.

Int J Surg Pathol. 2011 Oct;19(5):685-91. doi: 10.1177/1066896909341803. Epub 2009 Aug 5.

PMID:
19661098
36.

T cell infiltrate predicts long-term survival following resection of colorectal cancer liver metastases.

Katz SC, Pillarisetty V, Bamboat ZM, Shia J, Hedvat C, Gonen M, Jarnagin W, Fong Y, Blumgart L, D'Angelica M, DeMatteo RP.

Ann Surg Oncol. 2009 Sep;16(9):2524-30. doi: 10.1245/s10434-009-0585-3. Epub 2009 Jul 1.

PMID:
19568816
37.

Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies.

Abdel-Wahab O, Mullally A, Hedvat C, Garcia-Manero G, Patel J, Wadleigh M, Malinge S, Yao J, Kilpivaara O, Bhat R, Huberman K, Thomas S, Dolgalev I, Heguy A, Paietta E, Le Beau MM, Beran M, Tallman MS, Ebert BL, Kantarjian HM, Stone RM, Gilliland DG, Crispino JD, Levine RL.

Blood. 2009 Jul 2;114(1):144-7. doi: 10.1182/blood-2009-03-210039. Epub 2009 May 6.

38.

ALK-positive anaplastic large cell lymphoma in a patient with chronic lymphocytic leukemia.

Liu T, He M, Carlson DL, Hedvat C, Teruya-Feldstein J.

Int J Surg Pathol. 2010 Oct;18(5):424-8. doi: 10.1177/1066896908324259. Epub 2008 Sep 14.

PMID:
18794171
39.

Isolation of avian paramyxovirus 1 from a patient with a lethal case of pneumonia.

Goebel SJ, Taylor J, Barr BC, Kiehn TE, Castro-Malaspina HR, Hedvat CV, Rush-Wilson KA, Kelly CD, Davis SW, Samsonoff WA, Hurst KR, Behr MJ, Masters PS.

J Virol. 2007 Nov;81(22):12709-14. Epub 2007 Sep 12.

40.

Tumor promoting properties of the ETS protein MEF in ovarian cancer.

Yao JJ, Liu Y, Lacorazza HD, Soslow RA, Scandura JM, Nimer SD, Hedvat CV.

Oncogene. 2007 Jun 7;26(27):4032-7. Epub 2007 Jan 8.

PMID:
17213815
41.

Patterns of expression of cell cycle/apoptosis genes along the spectrum of thyroid carcinoma progression.

Saltman B, Singh B, Hedvat CV, Wreesmann VB, Ghossein R.

Surgery. 2006 Dec;140(6):899-905; discussion 905-6.

PMID:
17188136
42.

Lysophosphatidic acid acyltransferase-beta (LPAAT-beta) is highly expressed in advanced ovarian cancer and is associated with aggressive histology and poor survival.

Diefenbach CS, Soslow RA, Iasonos A, Linkov I, Hedvat C, Bonham L, Singer J, Barakat RR, Aghajanian C, Dupont J.

Cancer. 2006 Oct 1;107(7):1511-9.

43.

Expression of epithelial membrane protein-2 is associated with endometrial adenocarcinoma of unfavorable outcome.

Wadehra M, Natarajan S, Seligson DB, Williams CJ, Hummer AJ, Hedvat C, Braun J, Soslow RA.

Cancer. 2006 Jul 1;107(1):90-8.

44.

The ETS protein MEF is regulated by phosphorylation-dependent proteolysis via the protein-ubiquitin ligase SCFSkp2.

Liu Y, Hedvat CV, Mao S, Zhu XH, Yao J, Nguyen H, Koff A, Nimer SD.

Mol Cell Biol. 2006 Apr;26(8):3114-23.

45.

Comparison of two antibodies for immunohistochemical evaluation of epidermal growth factor receptor expression in colorectal carcinomas, adenomas, and normal mucosa.

Bhargava R, Chen B, Klimstra DS, Saltz LB, Hedvat C, Tang LH, Gerald W, Teruya-Feldstein J, Paty PB, Qin J, Shia J.

Cancer. 2006 Apr 15;106(8):1857-62.

46.

Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma.

Hassoun H, Reich L, Klimek VM, Dhodapkar M, Cohen A, Kewalramani T, Zimman R, Drake L, Riedel ER, Hedvat CV, Teruya-Feldstein J, Filippa DA, Fleisher M, Nimer SD, Comenzo RL.

Br J Haematol. 2006 Jan;132(2):155-61.

PMID:
16398649
47.

Expression of p63 in diffuse large B-cell lymphoma.

Hedvat CV, Teruya-Feldstein J, Puig P, Capodieci P, Dudas M, Pica N, Qin J, Cordon-Cardo C, Di Como CJ.

Appl Immunohistochem Mol Morphol. 2005 Sep;13(3):237-42.

PMID:
16082248
48.

Hematopoietic stem cell mobilization with intravenous melphalan and G-CSF in patients with chemoresponsive multiple myeloma: report of a phase II trial.

Gupta S, Zhou P, Hassoun H, Kewalramani T, Reich L, Costello S, Drake L, Klimek V, Dhodapkar M, Teruya-Feldstein J, Hedvat C, Kalakonda N, Fleisher M, Filippa D, Qin J, Nimer SD, Comenzo RL.

Bone Marrow Transplant. 2005 Mar;35(5):441-7.

PMID:
15640822
49.

Differential expression patterns of c-REL protein in classic and nodular lymphocyte predominant Hodgkin lymphoma.

Xiao Q, Shen N, Hedvat CV, Moskowitz CH, Sussman LK, Filippa DA, Zelenetz AD, Houldsworth J, Chaganti RS, Teruya-Feldstein J.

Appl Immunohistochem Mol Morphol. 2004 Sep;12(3):211-5.

PMID:
15551733
50.

Wilms Tumor Gene (WT1) and p53 expression in endometrial carcinomas: a study of 130 cases using a tissue microarray.

Dupont J, Wang X, Marshall DS, Leitao M, Hedvat CV, Hummer A, Thaler H, O'Reilly RJ, Soslow RA.

Gynecol Oncol. 2004 Aug;94(2):449-55.

PMID:
15297187

Supplemental Content

Loading ...
Support Center